In-Depth Notes on HIV and AIDS
Overview of HIV and AIDS
- HIV (Human Immunodeficiency Virus) is the infectious agent, while AIDS (Acquired Immunodeficiency Syndrome) is the disease caused by the virus.
- HIV/AIDS presents an opportunity to explore the interplay between the immune system and a viral pathogen.
Historical Context
- HIV first recognized as a clinical entity in 1981.
- The virus has led to over 30 million deaths globally, with 37 million currently living with HIV.
Global Statistics (2012)
- Total infected: 35.3 million (Estimates range: 32.2 - 38.8 million).
- New infections: 2.3 million (Estimates range: 1.9 - 2.7 million).
- Sub-Saharan Africa holds the highest prevalence, with 25 million infected individuals.
Regional HIV/AIDS Statistics
- Breakdown of HIV prevalence within regions:
- Sub-Saharan Africa: 25.0 million
- North America and Western Europe: Lower prevalence rates
- Variability in prevalence rates highlights differing epidemic situations.
Origins of HIV
- HIV originated from cross-species transmission from African monkeys to humans.
- Two predominant types are:
- HIV-1: Most common globally (98% of cases).
- HIV-2: Mostly found in West Africa and generally less transmissible.
HIV-1 Subtypes
- Subtypes M, N, O, and P; subtype M accounts for over 90% of global infections.
- Emergence linked to various environmental and host factors in human populations.
Transmission of HIV
- Transmission requires a breach in physical barriers through:
- Micro-abrasions during sexual intercourse.
- Use of contaminated needles and blood products.
- Probability of Transmission: Various sites (e.g., vaginal, rectal) have differing probabilities of leading to HIV infection:
- Female genital (vagina): 1 in 200 - 1 in 2,000
- Male genital (rectum): 1 in 20 - 1 in 300
HIV Characteristics
- Structure: Enveloped RNA virus that utilizes reverse transcription to integrate into host DNA.
- Infection Mechanism: Targets CD4 T cells, weakening the immune response over time.
Immune Response to HIV
- The initial immune response involves CTLs (Cytotoxic T Lymphocytes) and antibodies, which can suppress the virus temporarily but ultimately fail.
- Key Factors Affecting Immune Control:
- Loss of CD4 T cells due to HIV infection.
- Development of antigenic variants that escape immune recognition.
Disease Progression
- As HIV damages CD4 T cells, it leads to a severe immunodeficiency state, known as AIDS, characterized by opportunistic infections.
- Typical symptoms of AIDS arise when CD4 counts fall below critical thresholds.
Opportunities and Challenges in Vaccine Development
- Developing an effective HIV vaccine remains a challenge due to the high mutation rates and antigenic variability of the virus.
- Strategies for vaccine development include the study of broadly neutralizing antibodies that can target multiple strains of HIV.
Genetic Resistance to HIV
- Certain genetic variations, such as the delta 32 mutation in the CCR5 gene, confer resistance to HIV infection, albeit rarely.
- Long-term non-progressors exhibit slow disease progression, maintaining low levels of viral load.
Current Status and Future Directions
- Cases of functionally cured patients (e.g., "Berlin Patient") provide avenues for future research on potential cures.
- Continued efforts are underway in vaccine research, focusing on eliciting broad immune responses effective against diverse HIV strains.
Conclusion
- HIV/AIDS remains a significant global health challenge, necessitating ongoing research for effective treatments and prevention strategies.